Please login to the form below

Not currently logged in
Email:
Password:

Erivedge

This page shows the latest Erivedge news and features for those working in and with pharma, biotech and healthcare.

NICE backs Pfizer’s Xeljanz for RA

NICE backs Pfizer’s Xeljanz for RA

Roche’s Erivedge (vismodegib) - which was made available via the old CDF in 2013 - is also set to be cut from the scheme, but patients who are currently receiving the drug

Latest news

  • Pfizer's SMO inhibitor boosts survival in blood cancer trial Pfizer's SMO inhibitor boosts survival in blood cancer trial

    There are already two SMO (smoothened) inhibitors on the market - Novartis' Odomzo (sonidegib) and Roche's Erivedge (vismodegib) - and both are approved to treat a form of skin cancer known as ... Sales of Erivedge were around $150m in the first nine

  • EU green light for Novartis' skin cancer therapy EU green light for Novartis' skin cancer therapy

    It will compete in the marketplace against Roche's Erivedge (vismodegib), another SMO inhibitor that has been on the market since 2012 and achieved sales of 72m Swiss francs ($75m) in ... Neither drug is expected to be a big seller thanks to the small

  • FDA approves four new medicines across multiple areas FDA approves four new medicines across multiple areas

    The pill will compete against Roche's Erivedge (vismodegib), which was the first oral drug for BCC to see approval in 2012, although neither medicine is expected to be a blockbuster

  • Novartis skin cancer drug clears pivotal trial Novartis skin cancer drug clears pivotal trial

    This pathway is also targeted by Roche's Erivedge (vismodegib), which was granted approval as a BCC therapy in the US in 2012 and in Europe last year. ... Erivedge sales rocketed more than 160 per cent to reach 75m Swiss francs ($84m) last year has been

  • Roche's Erivedge authorised in UK Roche's Erivedge authorised in UK

    Roche's Erivedge authorised in UK. Available for skin cancer patients through Cancer Drugs Fund. ... Roche also recently completed a phase II trial of Erivedge in non-recurring operable modular BCC, which is a less severe form of the disease.

More from news
Approximately 3 fully matching, plus 11 partially matching documents found.

Latest appointments

  • Chris Bowden joins Agios Chris Bowden joins Agios

    During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.

  • Curis looks to MedImmune and Takeda for new hires Curis looks to MedImmune and Takeda for new hires

    Curis also worked with Roche to Erivedge (vismodegib), which recently won approval for the treatment of advanced basal cell carcinoma (BCC).

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics